The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIV

Inclusion Criteria Concurrent Medication: Allowed: * Antiretroviral therapy. * Anti-PCP prophylaxis. * Maintenance or prophylaxis therapy for other opportunistic infections besides CMV. Patients must have: * Working diagnosis of HIV infection. * CD4 count \<= 100 cells/mm3. * Positive CMV serology (IgG) or CMV culture, in the absence of active disease, documented at any time prior to study entry. * Reasonably good health. * Life expectancy of at least 6 months. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Acute life-threatening illness. * Active lymphoma. * Hypersensitivity to acyclovir. * Lack of willingness or ability, in the opinion of the clinician, to comply with protocol requirements. Concurrent Medication: Excluded: * Vidarabine. * Amantadine hydrochloride (Symmetrel). * CMV hyperimmune globulin/intravenous immune globulin. * Cytarabine. * Fiacitabine (FIAC) or fialuridine (FIAU). * Foscarnet. * Intravenous ganciclovir. * HPMPC. * Idoxuridine. * Intravenous acyclovir. * Oral acyclovir at \> 1 g/day. * Other drugs with potential anti-CMV activity. Prior Medication: Excluded within 60 days prior to study entry: * Foscarnet. Excluded within 2 weeks prior to study entry: * Vidarabine. * Amantadine hydrochloride (Symmetrel). * CMV hyperimmune globulin/intravenous immune globulin. * Cytarabine. * Fiacitabine (FIAC) or fialuridine (FIAU). * Ganciclovir. * HPMPC. * Idoxuridine. * Intravenous acyclovir. * Oral acyclovir at \> 1 g/day. * Other drugs with potential anti-CMV activity.